A 52-year-old woman receiving cisplatin chemotherapy develops severe nausea and vomiting despite ondansetron monotherapy. Which feature best distinguishes aprepitant from ondansetron and justifies its addition to the regimen?

## Aprepitant vs Ondansetron: The NK1 Antagonist Advantage ### Clinical Context: Breakthrough CINV **Key Point:** Chemotherapy-induced nausea and vomiting (CINV) is mediated by multiple neurotransmitter systems: 1. **Serotonin (5-HT)** — released from gut enterochromaffin cells by chemotherapy 2. **Substance P (NK1 ligand)** — released from vagal afferents and central neurons 3. **Dopamine** — in the chemoreceptor trigger zone Ondansetron alone blocks only the 5-HT3 pathway, leaving NK1-mediated emesis unchecked. ### Aprepitant: The NK1 Antagonist **High-Yield:** Aprepitant is a **selective neurokinin-1 (NK1) receptor antagonist** that: - Crosses the blood-brain barrier readily - Acts at the chemoreceptor trigger zone AND higher cortical/limbic centers involved in emesis - Has a long half-life (40–50 hours), providing sustained receptor occupancy - Blocks substance P, a key mediator of delayed CINV (occurs 24–120 hours post-chemotherapy) ### Why Aprepitant + Ondansetron is Superior to Ondansetron Alone | Mechanism | Ondansetron | Aprepitant | Combined Effect | |-----------|-------------|-----------|------------------| | **5-HT3 blockade** | ✓ (strong) | ✗ | Covers acute CINV | | **NK1 blockade** | ✗ | ✓ (strong) | Covers delayed CINV | | **Dopamine blockade** | ✗ | ✗ | — | | **BBB penetration** | Moderate | Excellent | Aprepitant reaches central sites | | **Onset** | Rapid (minutes) | Slower (hours) | Complementary timing | **Clinical Pearl:** Delayed CINV (24–120 hours post-chemotherapy) is driven primarily by **substance P**, not serotonin. This is why NK1 antagonists are essential for highly emetogenic regimens (e.g., cisplatin). Ondansetron monotherapy fails in ~30–40% of patients receiving highly emetogenic chemotherapy because it does not address the NK1 pathway. **Mnemonic:** **CINV = 5-HT + NK1 + DA** - Acute phase (0–24 hrs): dominated by 5-HT → ondansetron works - Delayed phase (24–120 hrs): dominated by NK1 → aprepitant needed - Combine both for complete coverage in high-risk patients **Warning:** Do not assume that adding a second 5-HT3 antagonist (e.g., granisetron) will improve breakthrough CINV. The problem is not inadequate 5-HT3 blockade; it is lack of NK1 antagonism.